Carnegie acted as joint bookrunner in connection with the financing round in SpinChip Diagnostics, successfully securing NOK 43 million in the form of a convertible loan.
Representing the future of point-of-care testing, SpinChip Diagnostics was founded in Norway in 2012. SpinChip’s proprietary platform is focused on in vitro diagnostics (IVD) to develop diagnostic tests for acute and chronic cardiac indications where test results are rapidly needed to provide patients with life-saving treatments.